BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33548251)

  • 1. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.
    Honma N; Ogata H; Yamada A; Matsuda Y; Kontani K; Miyashita M; Arai T; Sasaki E; Shibuya K; Mikami T; Sawaki M
    Hum Pathol; 2021 May; 111():10-20. PubMed ID: 33548251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice.
    Losurdo A; De Sanctis R; Fernandes B; Torrisi R; Masci G; Agostinetto E; Gatzemeier W; Errico V; Testori A; Tinterri C; Roncalli M; Santoro A
    Sci Rep; 2020 Nov; 10(1):20100. PubMed ID: 33208857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
    Teoh PY; Tan GC; Mahsin H; Wong YP
    Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
    Astvatsaturyan K; Yue Y; Walts AE; Bose S
    PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer.
    Lyalkin SA; Verevkina NO; Alekseyenko OO; Syvak LA
    Exp Oncol; 2020 Jun; 42(2):140-143. PubMed ID: 32602289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
    Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
    Zhang L; Wang XI; Zhang S
    Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
    Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.